These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 14991828)

  • 21. Pallidonigroluysian atrophy associated with p.A152T variant in MAPT.
    Graff-Radford J; Whitwell JL; Dickson DW; Josephs KA
    Parkinsonism Relat Disord; 2013 Sep; 19(9):838-41. PubMed ID: 23692670
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of MAPT and APOE on prognosis of progressive supranuclear palsy.
    Baba Y; Putzke JD; Tsuboi Y; Josephs KA; Thomas N; Wszolek ZK; Dickson DW
    Neurosci Lett; 2006 Sep; 405(1-2):116-9. PubMed ID: 16839689
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tau and saitohin gene expression pattern in progressive supranuclear palsy.
    Ezquerra M; Gaig C; Ascaso C; Muñoz E; Tolosa E
    Brain Res; 2007 May; 1145():168-76. PubMed ID: 17320831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progressive supranuclear palsy in the molecular age.
    Golbe LI
    Lancet; 2000 Sep; 356(9233):870-1. PubMed ID: 11036887
    [No Abstract]   [Full Text] [Related]  

  • 25. Association of an extended haplotype in the tau gene with progressive supranuclear palsy.
    Baker M; Litvan I; Houlden H; Adamson J; Dickson D; Perez-Tur J; Hardy J; Lynch T; Bigio E; Hutton M
    Hum Mol Genet; 1999 Apr; 8(4):711-5. PubMed ID: 10072441
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Autonomic dysfunction in patients with progressive supranuclear palsy.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Reichmann H; Berg D; Ziemssen T
    Mov Disord; 2008 Oct; 23(14):2083-9. PubMed ID: 18792126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association, expression, pathobiology: is too much tau in PD a blueprint for genetic association?
    Singleton A; Morris H
    Neurology; 2008 Jul; 71(1):11-2. PubMed ID: 18591501
    [No Abstract]   [Full Text] [Related]  

  • 28. Genetic influences on cognition in progressive supranuclear palsy.
    Gerstenecker A; Roberson ED; Schellenberg GD; Standaert DG; Shprecher DR; Kluger BM; Litvan I
    Mov Disord; 2017 Dec; 32(12):1764-1771. PubMed ID: 29076559
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient page. Progressive supranuclear palsy.
    Karceski S
    Neurology; 2008 Nov; 71(22):e70-2. PubMed ID: 19029512
    [No Abstract]   [Full Text] [Related]  

  • 30. Phenotypic associations of tau and ApoE in Parkinson's disease.
    Papapetropoulos S; Farrer MJ; Stone JT; Milkovic NM; Ross OA; Calvo L; McQuorquodale D; Mash DC
    Neurosci Lett; 2007 Mar; 414(2):141-4. PubMed ID: 17204369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features and disease haplotypes of individuals with the N279K tau gene mutation: a comparison of the pallidopontonigral degeneration kindred and a French family.
    Tsuboi Y; Uitti RJ; Delisle MB; Ferreira JJ; Brefel-Courbon C; Rascol O; Ghetti B; Murrell JR; Hutton M; Baker M; Wszolek ZK
    Arch Neurol; 2002 Jun; 59(6):943-50. PubMed ID: 12056930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinsonism.
    Hauser MA; Li YJ; Xu H; Noureddine MA; Shao YS; Gullans SR; Scherzer CR; Jensen RV; McLaurin AC; Gibson JR; Scott BL; Jewett RM; Stenger JE; Schmechel DE; Hulette CM; Vance JM
    Arch Neurol; 2005 Jun; 62(6):917-21. PubMed ID: 15956162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tau gene mutations and their effects.
    Goedert M
    Mov Disord; 2005 Aug; 20 Suppl 12():S45-52. PubMed ID: 16092090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease.
    Mamah CE; Lesnick TG; Lincoln SJ; Strain KJ; de Andrade M; Bower JH; Ahlskog JE; Rocca WA; Farrer MJ; Maraganore DM
    Ann Neurol; 2005 Mar; 57(3):439-43. PubMed ID: 15732111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
    Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
    Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects on splicing and protein function of three mutations in codon N296 of tau in vitro.
    Grover A; DeTure M; Yen SH; Hutton M
    Neurosci Lett; 2002 Apr; 323(1):33-6. PubMed ID: 11911984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pupil diameter in darkness differentiates progressive supranuclear palsy (PSP) from other extrapyramidal syndromes.
    Schmidt C; Herting B; Prieur S; Junghanns S; Schweitzer K; Globas C; Schöls L; Antoni S; Ferger D; Reichmann H; Wilhelm H; Berg D; Ziemssen T
    Mov Disord; 2007 Oct; 22(14):2123-6. PubMed ID: 17853484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressive supranuclear palsy.
    Warren NM; Burn DJ
    Pract Neurol; 2007 Feb; 7(1):16-23. PubMed ID: 17430861
    [No Abstract]   [Full Text] [Related]  

  • 39. Microtubule-associated protein tau (MAPT) influences the risk of Parkinson's disease among Indians.
    Das G; Misra AK; Das SK; Ray K; Ray J
    Neurosci Lett; 2009 Aug; 460(1):16-20. PubMed ID: 19450659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tau A0 allele in Parkinson's disease.
    Golbe LI; Lazzarini AM; Spychala JR; Johnson WG; Stenroos ES; Mark MH; Sage JI
    Mov Disord; 2001 May; 16(3):442-7. PubMed ID: 11391737
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.